An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia

American Journal of Managed Care

Volumn 6, Issue 3, 2000, Pages 381-389

  Rittenhouse, Brian E ^a,b   Stinnett, Aaron A ^a,f   Dulisse, Brian ^a   Henke, Curtis J ^c,d   Potter, Lori ^c   Parasuraman, Bhash ^a   Martens, Léon L ^a   Williams, R Rex ^e   Kojak, Clare ^e  

^a ICOM Health Economics   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c Lewin TAG Inc   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e R W JOHNSON PHARMACEUTICAL RES I   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFUROXIME AXETIL; LEVOFLOXACIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; DRUG COST; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RESOURCE MANAGEMENT; TREATMENT OUTCOME;

ADULT; AGED; AMBULATORY CARE; ANTI-INFECTIVE AGENTS; CEFUROXIME; CEPHALOSPORINS; DRUG COSTS; EVALUATION STUDIES; HUMANS; MIDDLE AGED; OFLOXACIN; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES;

EID: 0034026594     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995;333:1618-1624.
2. Klugman KP, Capper T. Levofloxacin in vitro activity and synergistic activity in combination with other antibacterials against antibiotic-resistant S. pneumoniae, and selection of resistant mutants. Abstract E9. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:87.
3. Markus A, Isert D, Kiesel N, Seibert G. Killing activity of levofloxacin (LEV) and ciprofloxacin (CIP) against Streptococcus pneumoniae in vitro and in vivo. Abstract E30. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:90.
4. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-1972.
5. DeAbate CA. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir Care 1995;42:206-213.
6. Fogarty CM. A noncomparative study to evaluate the safety and efficacy of levofloxacin in the treatment of community-acquired pneumonia in adults. Presented at the International Congress of Chemotherapy; July 17-19, 1995; Montreal, Quebec, Canada.
7. Sydnor TA, Scheld WM, Gwaltney JM. A noncomparative study to evaluate the safety and efficacy of levofloxacin in the treatment of acute bacterial sinusitis in adults. Presented at the International Congress of Chemotherapy; July 17-19, 1995; Montreal, Quebec, Canada.
8. Fu KP, Lafredo SC, Foleno B, et al. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 1992;36:860-866.
9. Fujimoto T, Mitsuhashi S. In vitro antibacterial activity; of DR-3355, the S-(-)isomer of ofloxacin. Chemotherapy 1990;36:268-276.
10. Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992;36:1573-1574.
11. Une T, Fujimoto T, Sato K, Osada Y. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother 1988;32:1336-1340.
12. File TM. Fluoroquinolones and respiratory tract infections: Do they work? Infect Dis Clin Pract 1997;6(suppl 2):S59-S66.
13. Chien S-C, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500 milligram oral or intravenous doses. Antimicrob Agents Chemother 1997;41:2256-2260.
14. Bonnet JP, Ginsberg D, Nolen TM. Cefprozil vs. cefuroxime axetil in mild to moderate lower respiratory tract infections: Analysis of patients with bronchitis. Infect Med 1992;9(suppl E):48-56.
15. Cooper TJ, Ladusans E, Williams PEO, et al. A comparison of oral cefuroxime axetil and oral amoxicillin in lower respiratory tract infections. J Antimicrob Chemother 1985;16:373-378.
16. Schleupner CJ, Anthony WC, Tan J, et al. Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections. Arch Intern Med 1988;148:343-348.
17. Bittner MJ, Pugsley MD, Horowitz EA, et al. Randomized comparison of ceftriaxone and cefamandole therapy in lower respiratory tract infections in an elderly population. J Antimicrob Chemother 1986;18:621-627.
18. Grassi C, Mangianotti P. International experiences with ceftriaxone in the treatment of lower respiratory tract infections. Chemotherapia 1987;6:364-373.
19. Mandell LA, Bergeron MG, Ronald AR, et al. Once-daily ceftriaxone compared with daily multiple dose therapy with cefotaxime for serious bacterial infections: A randomized double-blind study. J Infect Dis 1989;150:443-447.
20. Potgieter PD, Linton DM, Forder AA, Plumb H. Ceftriaxone therapy in adults with severe lower respiratory tract infections. S Afr Med J 1986;69:495-497.
21. National Prescription Audit Plus. Plymouth Meeting, PA: IMS America;1996.
22. Retail Perspective and Provider Perspective. Plymouth Meeting, PA: IMS America;1996.
23. National Disease and Therapeutic Index. Plymouth Meeting, PA: IMS America;1996.
24. Rittenhouse BE, Stinnett AA, Dulisse B, et al. An economic evaluation of levofloxacin versus ceftriaxone in the inpatient treatment of adults with community-acquired pneumonia. P & T 1999;24:159-179.
25. O'Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994;32:150-163.
26. Physician Payment Review Commission. Annual Report to Congress. Washington, D.C: PPRC;1993.
27. Red Book. Montvale, NJ: Medical Economics Company; December 1997;16(12):26,44.
28. Hsiao WC, Braun P, Dunn D, Becker E. Resource-based relative values: An overview. JAMA 1988;260:2347-2353.
29. Finkler SA. The distinction between costs and charges. Ann Intern Med 1982;96:102-109.
30. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:207,363.
31. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Programmes. Oxford, England: Oxford Medical Publications;1987:5-7.
32. Rittenhouse BE, O'Brien BJ. Threats to the validity of pharmacoeconomic analyses based on clinical trial data. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers;1996:1215-1224.
33. Cromer BA. Behavioral strategies to increase compliance in adults. In: Cramer JA, Spilker B, eds. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press; 1991:99-105.